Syndax Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Syndax Pharmaceuticals Inc.
Hartford Healthcare Fund
595,201
2.41%
-10,911
0.28%
07/31/2018
Vanguard Total Stock Market Index Fund
409,853
1.66%
0
0%
07/31/2018
Fidelity Select Biotechnology Portfolio
394,253
1.6%
0
0.03%
07/31/2018
iShares Russell 2000 ETF
310,357
1.26%
-165
0.01%
09/06/2018
BlackRock Health Sciences Opportunities Portfolio
288,521
1.17%
0
0.03%
06/29/2018
iShares Nasdaq Biotechnology ETF
286,615
1.15%
-3,738
0.02%
09/06/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
281,294
1.13%
91,294
0.1%
12/31/2017
Vanguard Extended Market Index Fund
259,998
1.05%
0
0%
07/31/2018
Tekla Life Sciences Investors
200,000
0.81%
0
0.32%
12/31/2017
DFA US Small Cap Portfolio
143,735
0.57%
71,332
0.01%
04/30/2018
| Address |
35 Gatehouse Drive
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.syndax.com |
| Updated |
07/08/2019 |
| Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. |
